Neuropsychopharmacology Reviews

Top

Editorial

Editorial: 'CNS Drug Discovery and Development: When Will We Rescue Tantalus?' Neuropsychopharmacology Reviews Volume 2 on CNS Drug Discovery and Development: Challenges and Opportunities

Husseini K Manji and Errol B DeSouza

Top

Commentary

Commentary: Physician–Scientist's Frustrations Fester

Floyd E Bloom

Neuropsychopharmacology 34: 1-5; doi:10.1038/npp.2008.181

Top

Neuropsychopharmacology Reviews

The Medical and Economic Roles of Pipeline Pharmacogenetics: Alzheimer's Disease as a Model of Efficacy and HLA-B*5701 as a Model of Safety

Allen D Roses

Neuropsychopharmacology 34: 6-17; advance online publication, October 15, 2008; doi:10.1038/npp.2008.153

Target Identification for CNS Diseases by Transcriptional Profiling

C Anthony Altar, Marquis P Vawter and Stephen D Ginsberg

Neuropsychopharmacology 34: 18-54; advance online publication, October 15, 2008; doi:10.1038/npp.2008.172

In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination

Jean E Merrill

Neuropsychopharmacology 34: 55-73; advance online publication, September 17, 2008; doi:10.1038/npp.2008.145

Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models

Athina Markou, Christian Chiamulera, Mark A Geyer, Mark Tricklebank and Thomas Steckler

Neuropsychopharmacology 34: 74-89; advance online publication, October 1, 2008; doi:10.1038/npp.2008.173

Non-Human Primates: Model Animals for Developmental Psychopathology

Eric E Nelson and James T Winslow

Neuropsychopharmacology 34: 90-105; advance online publication, September 17, 2008; doi:10.1038/npp.2008.150

Drugability of Extracellular Targets: Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion Channels

Dimitri E Grigoriadis, Samuel R J Hoare, Sandra M Lechner, Deborah H Slee and John A Williams

Neuropsychopharmacology 34: 106-125; advance online publication, September 17, 2008; doi:10.1038/npp.2008.149

Small Molecule Protein—Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

Levi L Blazer and Richard R Neubig

Neuropsychopharmacology 34: 126-141; advance online publication, September 17, 2008; doi:10.1038/npp.2008.151

Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets

Errol B De Souza, Sharon T Cload, Patrick Shannon Pendergrast and Dinah W Y Sah

Neuropsychopharmacology 34: 142-158; advance online publication, August 27, 2008; doi:10.1038/npp.2008.115

Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders

Jose de Leon

Neuropsychopharmacology 34: 159-172; advance online publication, September 17, 2008; doi:10.1038/npp.2008.147

Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases

Rima Kaddurah-Daouk and K Ranga Rama Krishnan

Neuropsychopharmacology 34: 173-186; advance online publication, October 8, 2008; doi:10.1038/npp.2008.174

The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development

Dean F Wong, Johannes Tauscher and Gerhard Gründer

Neuropsychopharmacology 34: 187-203; advance online publication, October 8, 2008; doi:10.1038/npp.2008.166

Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders

Philip S Wang, Robert Heinssen, Molly Oliveri, Ann Wagner and Wayne Goodman

Neuropsychopharmacology 34: 204-212; advance online publication, October 1, 2008; doi:10.1038/npp.2008.170

Challenges in Developing Novel Treatments for Childhood Disorders: Lessons from Research on Anxiety

Daniel S Pine, Sarah M Helfinstein, Yair Bar-Haim, Eric Nelson and Nathan A Fox

Neuropsychopharmacology 34: 213-228; advance online publication, August 27, 2008; doi:10.1038/npp.2008.113

NIMH Initiatives to Facilitate Collaborations Among Industry, Academia, and Government for the Discovery and Clinical Testing of Novel Models and Drugs for Psychiatric Disorders

Linda S Brady, Lois Winsky, Wayne Goodman, Mary Ellen Oliveri and Ellen Stover

Neuropsychopharmacology 34: 229-243; advance online publication, September 17, 2008; doi:10.1038/npp.2008.125

Top

Hot Topics

Adult neurogenesis, cell cycle and drug discovery in psychiatry

Robert N Pechnick and Vera Chesnokova

Neuropsychopharmacology 34: 244; doi:10.1038/npp.2008.164

Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse

Linda P Dwoskin and Michael T Bardo

Neuropsychopharmacology 34: 244-246; doi:10.1038/npp.2008.157

RNA editing as a therapeutic target for CNS disorders

Michael V Morabito and Ronald B Emeson

Neuropsychopharmacology 34: 246; doi:10.1038/npp.2008.159

The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?

Toni S Shippenberg

Neuropsychopharmacology 34: 247; doi:10.1038/npp.2008.165

Protein–protein interactions as therapeutic targets in neuropsychopharmacology

Matthew T Reilly, Kathryn A Cunningham and Amarnath Natarajan

Neuropsychopharmacology 34: 247-248; doi:10.1038/npp.2008.167

Promise of mGluR2/3 activators in psychiatry

P Jeffrey Conn and Carrie K Jones

Neuropsychopharmacology 34: 248-249; doi:10.1038/npp.2008.156

Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?

Geoffrey T Swanson

Neuropsychopharmacology 34: 249-250; doi:10.1038/npp.2008.158

Gene expression profiling in blood: new diagnostics in alcoholism and addiction?

R Dayne Mayfield and R Adron Harris

Neuropsychopharmacology 34: 250-251; doi:10.1038/npp.2008.162

From rapid In Vitro screening to rapid In Vivo screening in the drug discovery process

F Ivy Carroll and Richard A Houghten

Neuropsychopharmacology 34: 251-252; doi:10.1038/npp.2008.160

Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes

Oliver J Marston and Lora K Heisler

Neuropsychopharmacology 34: 252-253; doi:10.1038/npp.2008.169

Turning up the pace of ion channel screening in drug discovery

John Dunlop

Neuropsychopharmacology 34: 253; doi:10.1038/npp.2008.163

Lewy body pathology in long-term fetal nigral transplants: is parkinson's disease transmitted from one neural system to another?

Jeffrey H Kordower and Patrik Brundin

Neuropsychopharmacology 34: 254; doi:10.1038/npp.2008.161

Main navigation

ACNP resources

NPG resources

Extra navigation

21 November 2019

ADVERTISEMENT